NCT00533910

Rifaximin in Minimal Hepatic Encephalopathy

Effect of Rifaximin on Driving Performance, Psychometric Test Performance and Quality of Life in Cirrhotic Patients With Minimal Hepatic Encephalopathy: Randomized, Double-blind, Placebo-controlled Trial.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center · Federal
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether alteration of gut flora with rifaximin can lead to improvement in driving performance, psychometric test performance, and quality of life in patients with minimal hepatic encephalopathy (MHE) and cirrhosis in a randomized, blinded, placebo-controlled trial.

Conditions

• Hepatic Encephalopathy

Interventions

Type	Name	Description
DRUG	Rifaximin	550mg BID rifaximin for 8 weeks
DRUG	placebo	same as the experimental arm

Timeline

• Start date: 2007-10-01
• Primary completion: 2010-04-01
• Completion: 2010-05-01
• First posted: 2007-09-24
• Last updated: 2020-12-17
• Results posted: 2020-12-17

Locations

1 site across 1 country: United States